Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. O'Day K, Meyer K, Stafkey-Mailey D, Watson C J Med Econ. 2014 Nov 25:1-22. PMID: 25422991. Abstract CommentRecommendBookmarkWatch